The Epstein ± Barr virus (EBV) encoded Latent Membrane Protein-1 (LMP1) mimics a constitutively active receptor molecule, and has been shown to activate NFkB and the MAPK and JNK pathways. Two regions within the cytosolic domain of LMP1 have been found to eect cell signalling. One of these, the carboxy-terminal activation region-1 (CTAR1), binds members of the TRAF family of proteins, and the other (CTAR2) binds TRADD, suggesting that LMP1 transduces signals similarly to the Tumour Necrosis Factor Receptor family of receptors. The ability to bind TRAFs, to activate NFkB and the JNK pathway, to upregulate cellular genes such as CD54 (ICAM-1 adhesion molecule), and to aect cell growth and apoptosis has led to the suggestion that LMP1 signalling is similar to, or even identical to CD40. However, we now show that while ligand-induced CD40 signalling is impaired in the Jurkat T cell line, LMP1 was fully functional; therefore demonstrating that LMP1 and CD40 signalling dier. Mutated LMP1 genes, in which one or other of the CTAR1 and CTAR2 domains was non-functional, behaved more like CD40 in being unable to upregulate the CD54 cell surface marker in Jurkat cells. However, the CTAR1 domain of LMP1, which shared a TRAF-binding sequence motif with CD40, diered from CD40 in being unable to activate NF-kB in Jurkat. Cotransfection experiments with LMP1 mutants demonstrated that CTAR1 can cooperative with CTAR2 on separate LMP1 molecules, provided that they exist within the same oligomeric complex.
Introduction
Infection of human resting B lymphocytes in vitro with Epstein ± Barr virus (EBV) results in the outgrowth of immortal lymphoblastoid cell lines (LCLs) (reviewed by Kie, 1996; Rickinson and Kie, 1996) . Infection with EBV in vivo is associated with a number of malignant diseases of lymphoid and epithelial origin (Rickinson and Kie, 1996) and the Latent membrane protein-1 (LMP1) is one of the few viral genes to be expressed both in LCL and in many EBV-associated malignancies. LMP1 is considered to be a classical oncogene because of its ability to fully transform immortal rodent ®broblast cell lines (Baichwal and Sugden, 1988; Wang et al., 1985) . In EBV-infected human cells, LMP1 is essential for immortalisation of resting B lymphocytes (Kaye et al., 1993) and for continued proliferation of the derived LCLs (Kilger et al., 1998) . Furthermore, expression of LMP1 in cell lines causes a plethora of eects, including changes in cell surface marker expression reminiscent of the activation process initiated by EBV infection of normal resting B cells; e.g. upregulation of CD23, CD40 and CD54 (Peng and Lundgren, 1992; Wang et al., 1988 Wang et al., , 1990 . LMP1 also eects cell cycle progression by initiating DNA synthesis in resting B cells (Peng and Lundgren, 1992) and by partially blocking B cell lines in the G 2 /M phase (Floettmann et al., 1996) . In addition, LMP1 can also protect cells from apoptosis. In B cells this protection is at least in part due to upregulation of anti-apoptotic proteins, Bcl-2 (Henderson et al., 1991; Rowe et al., 1994) and probably A20 (Laherty et al., 1992) . In non-B cells, LMP1 does not cause upregulation of Bcl-2 but does upregulate A20 (Fries et al., 1996; Laherty et al., 1992) . In epithelial cells LMP1 also inhibits cellular differentiation (Dawson et al., 1990) , which could be an important feature of LMP1's role in EBV-associated epithelial malignancies.
The signalling events involved in mediating LMP1 eects have begun to emerge. Thus, the NF-kB transcription factor was shown to be activated in response to LMP1 expression (HammarskjoÈ ld and Simurda, 1992) and, more recently, LMP1 was also shown to activate the JNK and MAPK kinase pathways (Eliopoulos and Young, 1998; Kieser et al., 1997; Roberts and Cooper, 1998) . At least four TNFreceptor associated factors (TRAF1, TRAF2, TRAF3 and TRAF5) and the tumor necrosis factor receptorassociated death domain protein (TRADD) have been reported to directly associate with LMP1 Izumi and Kie, 1997; Mosialos et al., 1995; Sandberg et al., 1997) and thus potentially act as signal transducers.
The LMP1 molecule itself comprises a short Nterminal cytoplasmic domain, six membrane spanning helixes that anchor the protein in the membrane, and a long cytoplasmic carboxy-terminus. Two functional domains, the C-terminal activation region-1 (CTAR1) and -2 (CTAR2) have been identi®ed that are independently able to activate NF-kB in certain cells (Huen et al., 1995; Mitchell and Sugden, 1995; Paine et al., 1995) . Mutational analysis of CTAR1 has led to the identi®cation of a PxQxT motif, at residues 204 ± 208 in the 386 amino acid LMP1 protein of the B95.8 EBV isolate, that is essential for binding of TRAFs and CTAR1 mediated NF-kB activation Sandberg et al., 1997) . Similarly, a six amino acid sequence within the far carboxy terminus of the molecule, at 379 ± 384, was found to be essential for CTAR2 mediated NF-kB activation (Floettmann and Rowe, 1997) , and this region of CTAR2 binds TRADD (Izumi and Kie, 1997) .
In many respects, LMP1 appears to mimic a constitutively active CD40-like receptor. While extracellular binding of CD40-ligand mediates oligomerisation of CD40 molecules and subsequent association of TRAFs with the cytosolic tails of the receptor complex, LMP1 is constitutively active in a ligand-independent fashion through the spontaneous formation of oligomers via the multiple hydrophobic membranespanning regions. Similarities between CD40 and LMP1 functions include their ability to bind TRAFs through a PxQxT motif, and to activate both NF-kB and the JNK pathway. Furthermore, LMP1 and CD40 show remarkable similarities in their downstream eects upon cellular phenotype, including upregulation of a similar set of cell surface proteins (e.g. CD54), and in their eects upon cell dieration, proliferation and apoptosis (Eliopoulos et al., 1997; Kilger et al., 1998; van Kooten and Banchereau, 1997; ZimberStrobl et al., 1996) .
In the present work, we have compared LMP1 and CD40 signalling in dierent cell types, and show that there are dierences. We also addressed the question of the signi®cance of LMP1 having two separate functional domains. The results show that the CTAR1 and CTAR2 regions can physically cooperate with each other in oligomeric complexes of LMP1 molecules to generate a signalling event that is qualitatively distinct from the eects mediated by CTAR1 or CTAR2 alone.
Results

Cell-dependent dierences between LMP1 and CD40 signalling
It is well-established that LMP1 functions can be in¯uenced by the host cell type, and we have previously noted dierences in the ability of LMP1 to upregulate NF-kB and CD54 in B cell lines and T cell lines (Huen et al., 1995) . Furthermore, even though CD54 expression is regulated by NF-kB, there was not always a good correlation between NF-kB activation and CD54 induction by LMP1, suggesting that CD54 induction can be used as an indicator of LMP1 functions in addition to NF-kB activation. Therefore, in the ®rst set of experiments we compared the abilities of LMP1 and CD40 to activate NF-kB and to induce CD54 in the Eli-BL B cell line and in the Jurkat T cell line. The cells were transiently transfected with LMP1 or CD40 and activation of NF-kB was measured by cotransfection of a NF-kB-regulated luciferase reporter plasmid. Induction of CD54 was measured by¯ow-cytometric analysis of CD54 expression in the transfected cell subpopulation identi®ed by cotransfection of an expression vector for Green Fluorescent Protein (GFP); this assay is a modi®cation of that developed by Pilon et al. (1991) , which used CD2 as a marker gene for transfection eciency, and which is now a well established method for analysing LMP1 function (Huen et al., 1995; Peng and Lundgren, 1992; Rowe et al., 1994) .
As shown in Figure 1a , LMP1 and ligand-activated CD40 both activated NF-kB to similar levels in the Jurkat line. Jurkat is CD40-negative and, therefore, CD40L only caused activation of NF-kB in cells transfected with CD40. In contrast, Eli-BL cells expressed endogenous CD40 which was re¯ected in the observation that CD40L activated NF-kB in the vector control transfected Eli-BL cells. The CD40-mediated activation of NF-kB in Eli-BL was consistently slightly higher than the activation mediated by LMP1. However, it should be noted that in neither cell line was there a synergistic eect of LMP1 and ligated CD40 upon NF-kB activation, which is consistent with the hypothesis that the two receptors trigger similar signalling pathways activating NF-kB.
In addition to the activation of NF-kB in Eli-BL cells, ligation of exogenous and/or endogenous CD40 resulted in upregulation of cell surface CD54 that was more ecient that that induced by LMP1 (Figure 1b) . Importantly, while expression of LMP1 in Jurkat cells caused upregulation of CD54, ligation of CD40 completely failed to do so ( Figure 1b ) despite causing ecient activation of NF-kB. The CD54 results in Jurkat demonstrate a clear dierence in the signalling events following CD40 ligation and signalling from the constitutive active LMP1 complex.
The CD40-homologous TRAF-binding CTAR1 domain of LMP1 has dierent signalling properties to CD40
To identify possible reasons for the observed differences in LMP1 and CD40 mediated signalling, the eects of the individual CTAR1 and CTAR2 functional domains of LMP1 were examined by transfecting various LMP1 mutants into either Jurkat or Eli-BL. The premise for these experiments was that CTAR1 contains a TRAF binding domain that is very similar to the TRAF binding domain in CD40, whereas CTAR2 binds TRADD via a sequence that has no structural or functional homology with CD40. However, mutants that carried a deletion (LMP.349D) or a point mutation (LMP.Y384G) in CTAR2, and were thus functional in CTAR1 only, unexpectedly failed to activate NF-kB in Jurkat (Figure 2a ), which contrasts with the ability of CD40 to activate NF-kB in these cells (Figure 1a ). Even when greatly overexpressed relative to the amount of wild-type LMP1 required to give maximal NF-kB activation, these CTAR2-defective LMP1 mutants failed to activate NFkB (data not shown). Mutants carrying a deletion (LMP.186D352) or point mutations (LMP.AAA) in CTAR1 and which were thus functional in CTAR2 only, were shown to activate NF-kB to about 30% of wild-type LMP1 levels ( Figure 2a ) with maximal activation of about 40% achieved by greatly overexpressing either of the mutant LMP1 proteins. Thus, in Jurkat cells, neither CTAR1 nor CTAR2 alone was able to activate NF-kB as eciently as did wild-type LMP1, and CTAR1 function was most severely cotransfected with an NF-kB regulated luciferase reporter were assayed for luciferase at 24 h post-transfection. The basal luciferase activity obtained with vector control transfectants was subtracted from the activity of the other transfectants, and the data were normalized to the activity of wild-type LMP1 (100%). The results are the mean (+s.d.) of at least three separate experiments. The basal NFkB activity in Jurkat was barely detectable, and expression of LMP1 caused 50 ± 100-fold induction, whereas the basal NF-kB in Eli-BL was higher and expression of LMP1 caused only a 3 ± 5-fold activation of NF-kB. (b) cells cotransfected with a Green Fluorescence Protein marker gene were harvested at 48 h post-transfection for¯ow-cytometric immuno¯uorescence analysis of CD54 induction. CD54 was detected with a phycoerythrin-conjugated anti-CD54 monoclonal antibody and two-colour analysis was performed to quantitate the CD54 expression in the GFP-marked transfected cell population. The basal CD54 expression obtained with vector control transfectants was subtracted from the expression of the other transfectants, and the data were normalized to the activity of wildtype LMP1 (100%). The data for each construct are the mean (+s.d.) of at least three separate experiments impaired. In Eli-BL cells, CTAR1 demonstrated signi®cant activation of NF-kB that reached up to 35% of wild-type levels, but again CTAR2 was more ecient and showed about 75% of wild-type function ( Figure 2a ).
The dierent eciencies with which CTAR1 and CTAR2 domains of LMP1 activated NF-kB did not correlate with the ability to upregulate CD54 ( Figure  2b ). Thus, in Jurkat, CTAR1 or CTAR2 alone caused little or no upregulation of CD54 expression, whilst in Eli-BL cells, CTAR1 and CTAR2 each activated CD54 to about 50% of the levels achieved by wild-type LMP1. Therefore, in terms of NF-kB activation and CD54 upregulation, the eects of CD40 ligation are more closely mimicked by the non-homologous CTAR2 domain of LMP1 than by the PxQxT containing CTAR1.
CTAR1 and CTAR2 cooperate in LMP1-mediated upregulation of CD54
The above results con®rm and extend previous ®ndings (Huen et al., 1995) reporting cell type specific activation of NF-kB and upregulation of CD54 by LMP1 and LMP1 derived deletion-mutants. They also suggest that, at least Jurkat cells, both CTAR1 and CTAR2 are required to be functional in the same cell to activate CD54. We therefore performed a series of cotransfection experiments to test whether wild-type LMP1 function could be reconstituted by coexpression of mutant CTAR1 and CTAR2 LMP genes. This set of experiments was performed only in the Jurkat line since the results were expected to be more easily interpreted. As shown in Figure 3 , the LMP.Y384G mutant was again unable to activate NF-kB, while the LMP.AAA mutant activated NF-kB to about 25% of wild-type LMP1 levels; but coexpression of the two mutants caused a synergistic twofold increase in NFkB activation to about 50% of wild-type LMP1 levels. More remarkably, Figure 3 shows that although neither mutant alone was able to signi®cantly aect CD54 expression, cotransfection resulted in upregulation of CD54 to about 50% of levels achieved with wild-type LMP1. Similar results were obtained when the LMP.Y384G CTAR2-inactive mutant was substituted with the LMP.349D CTAR2 deletion mutant (data not shown). This demonstrates that ecient upregulation of CD54 in Jurkat cells requires the presence of functional CTAR1 as well as functional CTAR2 in the transfected cell.
A Western blot of LMP1 and mutants used in this study is shown in Figure 4 . The results show that the dierent LMP1 mutants were expressed at comparable levels and that cotransfection of LMP1 mutants did not result in increased expression of the individual mutant proteins which by itself could theoretically result in increased upregulation of CD54. As has been documented previously (Huen et al., 1995) , the LMP1(186D352) was not detectable by Western blotting but expression was con®rmed by immunouorescence staining with the CS.1 antibody, and it appeared to be expressed comparably to the other LMP1 mutants. Furthermore, as shown in Figure 2 , the LMP1(186D352) mutant was clearly functional in the Eli-BL cell line.
Cooperation of CTAR1 and CTAR2 occurs within the same oligomeric LMP1 complex
The observed cooperation between CTAR1 and CTAR2 ( Figure 3 ) could arise in one of two possible ways: either two separate signalling events combine additively to eect full wild-type LMP1 function or, a physical association (direct or indirect) between CTAR1 and CTAR2 initiates a qualitatively distinct signalling event. In the former scenario, cooperation could be achieved if CTAR1 and CTAR2 were active on LMP1 mutants that formed separate homooligomers; whilst the latter scenario would only arise if CTAR1 and CTAR2 were present within the same hetero-oligomeric complex of LMP1 mutants. We therefore devised the following experiment to test these two possibilities. As described schematically in Figure 5 , two complementary CTAR1/CTAR2 mutants were designed with the intention that one mutant with an inactivated CTAR2 (LMP.Y384G) would spontaneously form homo-oligomers, whereas the second mutant (CD2-229), comprising a fusion protein of the transmembrane and extracellular domains of CD2 fused to residues 229 ± 386 of LMP1, would form separate oligomers upon cross-linking with extracellular anti-CD2 antibodies (Figure 5b and c) .
First, in order to demonstrate that CD2-LMP1 fusion proteins do indeed form oligomeric complexes separately from molecules containing the multiple membrane-spanning sequences of LMP1, immunopre- Figure 4 Western blot demonstrating expression of the LMP1 mutants used in this study. Jurkat cells were transfected with the indicated LMP1 genes and were harvested after 24 h and processed for SDS ± PAGE and Western blotting. The blot was probed with the CS.1 ± 4 pool of monoclonal antibodies reactive with LMP1 Figure 3 Synergistic eect of CTAR1 and CTAR2 functional domains of LMP1. The LMP.Y384G and LMP.AAA mutant LMP1 genes were cotransfected into Jurkat cells, and compared with cells transfected with either one of the mutant genes or with wild-type LMP1. Activation of NF-kB (a) and induction of CD54 (b) were assayed as described in Figure 1 cipitation experiments were performed (Figure 6 ). Because the extracellular domain of rat CD2 is heavily glycosylated, the CD2-LMP1 fusion proteins migrate as broad bands on SDS-polyacrylamide gel electrophoresis (SDS ± PAGE) and they characteristically show weaker bands of a lower molecular weight that may be incompletely glycosylated polypeptides or breakdown products. With the CD2-229 chimera, one of the lower molecular-weight bands migrated similarly to wild-type LMP1 which complicated interpretation of coimmunoprecipitation experiments. In these experiments, therefore, we used the CD2-192 chimera containing LMP1 residues 192 ± 386 (i.e. including CTAR1) which was preferable because it produced a larger protein that was clearly distinguished from wildtype LMP1 on SDS ± PAGE. Jurkat cells were cotransfected with dierent combinations of LMP1 mutants and fusion proteins and, after 18 h culture, the membrane proteins were solubilized with NP40 detergent and immunoprecipitated with anti-CD2 antibody. Western blots of the immunoprecipitates were then probed with LMP1-speci®c monoclonal antibodies. As seen in Figure 6 , cells expressing LMP.Y384G alone did not yield LMP1 sequences with anti-CD2 immunoprecipitates. Cells coexpressing both LMP.Y384G and CD2-192 also failed to yield any LMP.Y384G in the anti-CD2 immunoprecipitates, although the CD2-192 was quantitatively recovered. As a positive control for these experiments, LMP.Y384G was coexpressed with the CD2-LMP1 chimera which comprised a full-length LMP1 (1 ± 386) fused at its amino terminus to the transmembrane and extracellular domains of CD2; this chimera is known to be spontaneously functional (Floettmann and Rowe, 1997) and is therefore assumed to spontaneously form oligomers. In this control immunoprecipitation the LMP.Y384G was shown to associate with the CD2-LMP1 protein. Thus, the lack of multiple tansmembrane regions in the CD2-192 and CD2-229 chimerae abrogates their ability to form hetero-oligomers with LMP1, but they do form homo-oligomers with themselves following antibody-mediated cross-linking via the CD2 domain.
As shown in Figure 7a , the CD2-229 chimera was unable to activate NF-kB in its monomeric state but when cross-linked with anti-CD2 monoclonal antibodies plus secondary rabbit anti-mouse IgG antibodies, activation of NF-kB was observed at levels slightly higher than were achieved with the LMP.AAA CTAR1-inactivated mutant. Cross-linking the CD2-229 protein caused a small increase in CD54 expression to the low levels obtained spontaneously with the Figure 5 A schematic representation of the experiment in which the LMP.Y384G mutant (functional CTAR1 domain only) and the CD2.229 fusion protein (functional CTAR2 domain only) were expressed as separate homo-oligomers. Schematic A shows the components of the CD2.229 chimeric protein which contains the extracellular and transmembrane domains of rat CD2 (nonfunctional) fused to the C-terminus of LMP1 which is deleted for CTAR1. Schematic B illustrates the plasma membrane localisation of coexpressed LMP.Y384G and CD2.229 proteins. The LMP.Y384G protein spontaneously forms functional homo-oligomers, while CD2.229 remains as scattered inactive monomers. Schematic C illustrates the eect of adding cross-linking antibodies directed to determinants on the extracellular CD2 domain of CD2.229 proteins. Now, the CD2.229 proteins are induced to oligomerise, with concommitent activation of CTAR2 function, but these oligomers remain separate from the LMP.Y384 oligomers reference LMP.AAA mutant (Figure 7b) . Crucially, when compared to the synergistic eect of coexpressing LMP.AAA and LMP.Y384G upon CD54 induction, the cross-linked CD2-229 protein showed only a slight additive eect upon CD54 when coexpressed with LMP.Y384G despite showing similar levels of NF-kB activation to contransfected LMP.Y284G/LMP.AAA (Figure 7a ). These results demonstrate that CTAR1 and CTAR2 have to locate to the same oligomeric complex in order to synergistically aect upregulation of CD54.
Discussion
We have shown that CD40L treatment of Jurkat T cells transfected with CD40 causes activation of NFkB, but not upregulation of CD54. This is in contrast to LMP1 mediated signalling which results in activation of NF-kB and also upregulation of cell surface CD54. This observation highlights the fact that NF-kB activation alone is not sucient to activate CD54 in Jurkat cells, and it indicates the requirement for additional signal factor(s). Since the ability of activated CD40 to upregulate CD54 was demonstrated here in the Eli-BL B cell line, the results with the Jurkat line demonstrate that CD40 mediated signalling may somehow be impaired in certain host cells while LMP1 signalling is unaected. A subsequent investigation of a wider panel of BL lines (Henriquez et al., 1998) showed that while most BL lines tested were responsive to CD40 signalling, as was the Eli-BL line studied in the present work, some BL lines were clearly defective for CD40 signalling while retaining the ability to eciently transduce LMP1 signals. Therefore, the Jurkat T cell line is not unique in dislaying dierential ability to support CD40 and LMP1 signals. These observations indicate the use of dierent signalling pathways by CD40 and LMP1 which usually converge to eect similar downstream functions. Therefore, if one subscribes to the view that LMP1 mimics CD40, this could give LMP1 the advantage to remain fully functional in cellular backgrounds in which CD40 signalling is impaired.
Although CD40 and LMP1 each have two domains that are able to activate NF-kB, only one of each pair Figure 1 shows signi®cant sequence homology. Thus, a TRAF binding PxQxT motif is present in CD40 at aa 250 ± 254 and also in the CTAR1 region of LMP1 at aa 204 ± 208. Interestingly, while LMP1 CTAR1 was reported to bind TRAF1 as well as TRAF2, TRAF3 and TRAF5 through its PxQxT motif (Brodeur et al., 1997; Devergne et al., 1996; Mosialos et al., 1995; Sandberg et al., 1997) , CD40 seems to associate only with TRAF2 and TRAF3 through this motif (Ishida et al., 1996; Rothe et al., 1995) . It has been noted that dierences in the sequences adjacent to the PxQxT motif may in¯uence TRAF binding and signalling from CD40 and LMP1 (Eliopoulos et al., 1997; Franken et al., 1996) . It is possible, therefore, that the inability of TRAF1 to bind CD40 could explain dierences between CD40 and LMP1 mediated signals. Similarly it has been observed that while overexpression of TRAF1 potentiates LMP1-mediated NF-kB activation , it has no eect on CD40-mediated NF-kB activation (Rothe et al., 1995) . There is no sequence homology between the second NF-kB activation domain within CD40, which maps to the TRAF6 binding at aa 230 ± 245 (Ishida et al., 1996) , and either CTAR1 or CTAR2 of LMP1. Furthermore, TRAF6 appears not to be directly involved in LMP1-mediated signalling (Brodeur et al., 1997) . Therefore, despite the presence of a functional PxQxT TRAF binding motif in CD40 and LMP1, the only evidence that CD40 and LMP1 utilize the same mechanisms to activate NF-kB comes from experiments where dominant-negative TRAF2 over-expression was shown to block NF-kB activation from both molecules Rothe et al., 1995) . However, rather than directly interacting with other TRAFs at the receptor, the eects of dominant-negative TRAF2 could result from an interference with other signal complexes further down the pathway. This was demonstrated by the ability of TRAF2 to interfere with NF-kB activation from LMP1 CTAR2 which itself does not bind TRAF2 directly .
It is conceivable that the dierent mechanisms by which CD40 and LMP1 activate NF-kB may result in the translocation of dierent NF-kB species to the nucleus. Whilst both CD40 and LMP1 are reported to activate p50/RelA heterodimers (Herrero et al., 1995; Rothe et al., 1995) it is not clear that this is sucient to activate CD54 gene expression; it has been reported that RelA/cRel heterodimers may play a crucial role in CD54 gene expression (Ledebur and Parks, 1995) . Alternatively, or in addition, it is possible that other signalling pathways such as the SEK/JNK/AP1 pathway (Reinhard et al., 1997) normally activated by the association of TRAF2 with members of the TNFreceptor superfamily, or even the MAPK pathway (Roberts and Cooper, 1998) , are involved in regulation of CD54 gene expression and may be selectively impaired in Jurkat T cells but not in Eli-BL cells.
Whatever the reasons for the dierences between CD40 and LMP1 function in Jurkat cells, this line proved useful for investigating the structural requirements for LMP1 function. Consistent with previous reports that the extent of CTAR1 and CTAR2-mediated signalling in LMP1 mutants can vary with the cellular background (Huen et al., 1995) , we found that the Jurkat is defective for CTAR1 mediated activation of NF-kB and upregulation of CD54. In contrast, activation of NF-kB by CTAR2, was only partially impaired in Jurkat; nevertheless, LMP1 mutants active for CTAR2 alone were unable to upregulate CD54. Cotransfection experiments with mutated LMP1 genes in which either CTAR1 or CTAR2 was inactivated, showed that the CTAR1 and CTAR2 domains of LMP1 can cooperate to upregulate CD54. Using a chimeric CD2/CTAR2 construct it was possible to exclude the possibility of the observed cooperation between CTAR1 and CTAR2 being the additive eect of two independent signals from separate CTAR1 and CTAR2 homo-oligomers. Thus, coexpression of spontaneous oligomers of LMP.Y384G (functional CTAR1 only) and separate antibody-mediated oligomers of the CD2-229 (CD2/ LMP1 chimera with CTAR2 only) did not upregulate CD54. This demonstrates that cooperation between CTAR1 and CTAR2 has to occur within a heterooligomeric LMP1 complex. Furthermore, it suggests that this cooperation between CTAR1 and CTAR2 results in a signalling event that is qualitatively distinct from the signals generated by CTAR1 and CTAR2 separately.
The existence of a cooperative function between CTAR1 and CTAR2 of LMP1 gives further insight into how LMP1 signals. It also cautions against overinterpretation of data obtained with mutants nonfunctional for CTAR1 or CTAR2, and particularly with mutants containing large deletions that may adversely aect physical cooperation between CTAR1 and CTAR2. In agreement with this, there is evidence that dierences in signalling from individual CTAR1/2 domains and whole length LMP1 might result from changes in the components of the TRAF complexes bound to LMP1. Thus, aa 187 ± 386 of LMP1 bind less TRAF1 and 2 than deletion mutants encoding amino acids 187 ± 231 only Sandberg et al., 1997) .
These data with LMP1 raise the question of whether similar cooperation may occur between the two signalling domains of CD40. Intriguingly, it has been suggested that CD30 may undergo a conformational change when TRAF2 simultaneously engages both of its signalling domains (Boucher et al., 1997) . It is possible, therefore, that physical cooperation between two cytoplasmic signalling domains to produce a qualitatively new signalling event is a general feature of the CD40/TNFR superfamily of receptors.
Materials and methods
Cell lines
Jurkat is a cell line derived from a EBV negative T cell lymphoma (Brattsand et al., 1990) . Eli-BL is an EBVpositive B cell line established from a Burkitt's lymphoma and it displays a latency I form of infection in which EBNA1 is the only viral protein detected (Rowe et al., 1992) . All cells were grown in RPMI/10% FCS supplemented with 200 U of penicillin and 200 mg of streptomycin per ml at 378C in a 5% CO 2 atmosphere.
Plasmids
Most of the plasmids used in this work have been described elsewhere (Eliopoulos and Young, 1988; Floettmann and Rowe, 1997; Huen et al., 1995) . Plasmid pSG5-LMP1 expresses wildtype LMP1 cloned from the B95.8 virus, and was used to derive various mutants: plasmid pSG5-LMP.349D expresses LMP1 amino acids 1 ± 349; plasmid pSG5-LMP.186D351 expresses LMP1 deleted for amino acids 187 to 350; plasmid pSG5-LMP.Y384G expresses LMP1 with amino acid 384 changed from tyrosine to glycine; and plasmid pSG5-LMP.AAA expresses LMP1 with the amino acids proline 204, glutamine 206 and threonine 208 mutated to alanine. The pSG5-CD2 expresses a truncated rat CD2 protein (amino acids 1 ± 212) that lacks the cytosolic tail, and was used to generate chimeric CD2/ LMP1 proteins: pSG5-CD2-LMP1 expresses truncated CD2 fused to the amino terminus of the whole length LMP1 (amino acids 1 ± 386); pSG5-CD2-192 expresses truncated CD2 fused to amino acids 192 ± 386 of LMP1; and pSG5-CD2-229 expresses truncated CD2 fused to amino acids 229 ± 386 of LMP1. Plasmid pcDNA3-CD40 is a human CD40 expression vector (Eliopoulos and Young, 1998) . The Green Fluorescent Protein expression plasmid, pEGF-N1, was obtained from Clontech.
Gene transfection
All cell lines were transfected by electroporation using a Biorad Genepulser II electroporator. Cells were harvested by centrifugation and resuspended at 1.5610 7 cells/ml in growth medium. An aliquot of 0.5 ml was then added to the electroporation cuvette (Biorad, 0.4 mm width) and 2 mg) of each plasmid was added. After electroporation at 270 V and 950 mF, the cells were reseeded in 5 ml growth medium and incubated under normal conditions.
Oligomerisation of CD2 and ligation of CD40
Unless otherwise stated, oligomerisation of CD2/LMP1 chimeric proteins was induced by the addition of 5% culture supernatant of the OX34 hybridoma (Jeeries et al., 1985) which produces murine anti-CD2 monoclonal antibodies and addition of 1 : 100 polyclonal anti-mouse immunoglobulins Z0259 (Dako) which had been dialysed to remove the azide from the antibody preparation. Transfected and endogenous CD40 was ligated with 10 mg/ml CD40 ligand (Immunex).
Assay for NF-kB activity
The activity of NF-kB was assessed using a luciferase reporter plasmid with three kB elements upstream of a minimal conalbumin promoter driving the expression of the ®re¯y luciferase gene (Arenzana-Seisdedos et al., 1993) . At 24 h post-transfection, cells were washed twice in phosphate buered saline and lysed in 150 ml lysis buer containing 100 mM HEPES pH 8.0, 2 mM magnesium chloride, 5 mM dithiothreitol, and 2% Triton X-100. Luciferase activity was measured by adding 50 ml of clari®ed lysate to a scintilation tube and then analysing light release in a Berthold LB9501 luminometer following injection of 100 ml of 0.5 mM luciferin (USB) dissolved in Luciferin Assay Reagent (30 mM glycylglycin pH 7.9, 1 mM MgCl 2 , 0.1 mM EDTA, 30 mM DTT, 0.3 mM coenzyme A, 0.5 mM ATP). Light release was integrated for 10 s. The luciferase activity in each sample was normalised for variations in transfection eciency as determined by the percentage of GFP positive cells.
Flow-cytometric CD54 expression assay
Induction of CD54 expression by LMP1 was analysed bȳ ow-cytometry using Green Fluorescence Protein as a marker for transfected cells. The monoclonal antibody to human CD54 was phycoerytherin-conjugated (MCA675PE; Serotec) and staining was carried out with a single incubation at 08C for 60 min. Cells transfected with CD2/LMP1 chimeras that were incubated with cross-linking antibodies were pretreated with 20% normal mouse serum for 30 min at 08C prior to staining for CD54.
Detection of proteins by Western blotting
Cells were harvested and analysed for the expression of proteins by SDS ± polyacrylamide gel electrophoresis and Western blotting as previously described (Floettmann and Rowe, 1997) . Nitrocellulose transfers were blocked in Blotto (5% w/v dried skimmed milk in TBS) for 2 h before binding primary antibody. LMP1 and LMP1 encoding chimeras were detected using 1 mg/ml CS. 1 ± 4 (Rowe et al., 1987) in Blotto. All blots were incubated with 1 : 2000 dilution of rabbit antimouse IgG antibodies (Z0259: Dako) rabbit anti mouse diluted 1 : 2000 in Blotto followed by an incubation with goat anti-rabbit-alkaline phosphatase (Sigma; A-3812) diluted 1 : 10 000 in TBS-tween. Speci®c antibody-protein complexes were detected using a BCIP/NBT chromogenic substrate kit (Biorad).
Immunoprecipitations
Jurkat cells were electroporated with dierent combinations of expression plasmids, and 24 h later aliquots of 2610 7 cells were harvested, rinsed with cold phosphate balanced salt solution (PBS), and kept in a hypotonic buer (10 mM HEPES pH 7.9, 0.5 mM KCl, 0.5 mM MgCl 2 , 0.1 mM EGTA, 0.5 mM DTT) on ice for 30 min as described elsewhere . The cells were then dounced using a 27 gauge needle and lysates were centrifuged. The particulate fraction was resuspended in 400 ml cold TBS/0.5% NP40 and incubated on ice. After 30 min the lysate was centrifuged again and the supernatant was added to 100 ml of a Sepharose-Protein A beads (P-3391; Sigma) preincubated with rabbit anti-mouse IgG antibodies (Z0259; Dako) and OX34 murine antibodies to rat CD2. Following incubation on a rotating mixer at 48C overnight, the beads were washed three times in RIPA buer (50 mM Tris pH 7.5, 150 mM NaCl, 1% NP40, 0.5% Na deoxycholate, 0.1% SDS) and once in PBS. Beads were resuspended in 100 ml Gel Sample Buer (50 mM Tris pH 6.8, 4% SDS, 10% glycerol, 5% b-mercaptoethanol, 0.01% bromophenol blue), and boiled for 2 min prior to analysis by Western blotting.
